![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARHGAP36 |
Gene summary for ARHGAP36 |
![]() |
Gene information | Species | Human | Gene symbol | ARHGAP36 | Gene ID | 158763 |
Gene name | Rho GTPase activating protein 36 | |
Gene Alias | ARHGAP36 | |
Cytomap | Xq26.1 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q6ZRI8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
158763 | ARHGAP36 | PTCwithHT_8 | Human | Thyroid | HT | 1.68e-15 | 6.73e-01 | 0.0351 |
158763 | ARHGAP36 | PTCwithoutHT_7 | Human | Thyroid | PTC | 4.68e-08 | 7.32e-01 | 0.0381 |
158763 | ARHGAP36 | male-WTA | Human | Thyroid | PTC | 9.50e-14 | 2.77e-01 | 0.1037 |
158763 | ARHGAP36 | female-WTA | Human | Thyroid | PTC | 4.31e-10 | 6.06e-01 | 0.0726 |
158763 | ARHGAP36 | PTC04 | Human | Thyroid | PTC | 5.84e-60 | 3.10e+00 | 0.1927 |
158763 | ARHGAP36 | PTC05 | Human | Thyroid | PTC | 1.91e-04 | 5.53e-01 | 0.2065 |
158763 | ARHGAP36 | PTC06 | Human | Thyroid | PTC | 3.92e-13 | 8.74e-01 | 0.2057 |
158763 | ARHGAP36 | PTC07 | Human | Thyroid | PTC | 4.14e-42 | 1.42e+00 | 0.2044 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGAP36 | SNV | Missense_Mutation | c.1013C>A | p.Pro338His | p.P338H | Q6ZRI8 | protein_coding | deleterious(0) | possibly_damaging(0.769) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
ARHGAP36 | SNV | Missense_Mutation | rs866987298 | c.487N>T | p.Arg163Trp | p.R163W | Q6ZRI8 | protein_coding | tolerated(0.08) | probably_damaging(0.982) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ARHGAP36 | SNV | Missense_Mutation | rs763228565 | c.1624G>A | p.Val542Ile | p.V542I | Q6ZRI8 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ARHGAP36 | SNV | Missense_Mutation | c.1504N>A | p.Ala502Thr | p.A502T | Q6ZRI8 | protein_coding | tolerated(0.39) | benign(0.047) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGAP36 | SNV | Missense_Mutation | novel | c.463N>T | p.Val155Leu | p.V155L | Q6ZRI8 | protein_coding | tolerated(0.74) | benign(0.009) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
ARHGAP36 | insertion | Frame_Shift_Ins | novel | c.537_538insGAGCTGAGTCCTTTCGCCAAACCACTGCGGGGTCTTTTTGGCT | p.Thr180GlufsTer27 | p.T180Efs*27 | Q6ZRI8 | protein_coding | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
ARHGAP36 | SNV | Missense_Mutation | c.689N>T | p.Pro230Leu | p.P230L | Q6ZRI8 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-C5-A1BM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGAP36 | SNV | Missense_Mutation | c.54C>G | p.Ile18Met | p.I18M | Q6ZRI8 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ARHGAP36 | SNV | Missense_Mutation | c.451N>T | p.Arg151Trp | p.R151W | Q6ZRI8 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-EA-A3QE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ARHGAP36 | SNV | Missense_Mutation | c.1597N>T | p.Pro533Ser | p.P533S | Q6ZRI8 | protein_coding | tolerated_low_confidence(0.09) | probably_damaging(0.994) | TCGA-EA-A5FO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |